Sufentanil Sublingual Tablet: A New Option for Acute Pain Management

Reardon, Caitlin E; Kane‐Gill, Sandra L.; Smithburger, Pamela L.; Dasta, Joseph F.

doi:10.1177/1060028019863144

Cited by 13 publications

(7 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…25,35 Sufentanil is also available as sublingual tablet, with 53% bioavailability which blunts the high serum sufentanil levels seen with the IV route, decreasing the risk of adverse events with inappropriate use of high-dose IV sufentanil. 26…”

Section: Alternative Therapies For Analgesia In Covid-19 Patientsmentioning

confidence: 99%

Sedation, Analgesia, and Paralysis in COVID-19 Patients in the Setting of Drug Shortages

Ammar

Sacha

Welch

et al. 2020

J Intensive Care Med

Self Cite

View full text Add to dashboard Cite

The rapid spread of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has led to a global pandemic. The 2019 coronavirus disease (COVID-19) presents with a spectrum of symptoms ranging from mild to critical illness requiring intensive care unit (ICU) admission. Acute respiratory distress syndrome is a major complication in patients with severe COVID-19 disease. Currently, there are no recognized pharmacological therapies for COVID-19. However, a large number of COVID-19 patients require respiratory support, with a high percentage requiring invasive ventilation. The rapid spread of the infection has led to a surge in the rate of hospitalizations and ICU admissions, which created a challenge to public health, research, and medical communities. The high demand for several therapies, including sedatives, analgesics, and paralytics, that are often utilized in the care of COVID-19 patients requiring mechanical ventilation, has created pressure on the supply chain resulting in shortages in these critical medications. This has led clinicians to develop conservation strategies and explore alternative therapies for sedation, analgesia, and paralysis in COVID-19 patients. Several of these alternative approaches have demonstrated acceptable levels of sedation, analgesia, and paralysis in different settings but they are not commonly used in the ICU. Additionally, they have unique pharmaceutical properties, limitations, and adverse effects. This narrative review summarizes the literature on alternative drug therapies for the management of sedation, analgesia, and paralysis in COVID-19 patients. Also, this document serves as a resource for clinicians in current and future respiratory illness pandemics in the setting of drug shortages.

show abstract

Section: Alternative Therapies For Analgesia In Covid-19 Patientsmentioning

confidence: 99%

Sedation, Analgesia, and Paralysis in COVID-19 Patients in the Setting of Drug Shortages

Ammar

Sacha

Welch

et al. 2020

J Intensive Care Med

Self Cite

View full text Add to dashboard Cite

show abstract

“… 20 Compared with fentanyl, SUF has the advantages of stronger lipophilicity, higher plasma protein binding rate, relatively smaller volume of distribution, strong opioid receptor affinity and longer duration of action. 21 But so far, there are few reports about the protective effect of opioid pretreatment on the brain. In this experimental study, a rat CIRI model was established, and various doses of SUF were used at the same time.…”

Section: Discussionmentioning

confidence: 99%

Sufentanil alleviates cerebral ischemia-reperfusion injury by inhibiting inflammation and protecting the blood-brain barrier in rats

Wang

et al. 2022

Eur J Histochem

View full text Add to dashboard Cite

Stroke is a brain system disease with a high fatality rate and disability rate. About 80% of strokes are ischemic strokes. Cerebral ischemia-reperfusion injury (CIRI) caused by ischemic stroke seriously affects the prognosis of stroke patients. The purpose of this study is to investigate the effect of sufentanil (SUF) on CIRI model rats. We used middle cerebral artery occlusion (MCAO) to make the CIRI model in rats and monitored region cerebral blood flow (rCBF) to ensure that blood flow was blocked and recanalized. We used ELISA and RT-PCR to detect the expression of inflammatory factors in rat serum and brain tissue. In addition, we detected the expression of metalloproteinase (MMP) 2, MMP9 and collagen IV in brain tissues and performed Evans blue (EB) assay to determine the permeability of the blood-brain barrier (BBB). Finally, we clarified the apoptosis of brain tissue through the TUNEL staining and the detection of caspase3, Bcl2 and Bax. Various concentrations of SUF, especially 5, 10 and 25 μg/kg of SUF, all alleviated the infarct size, neurological function and brain edema of MCAO rats. SUF pretreatment also effectively reduced the expression of inflammatory cytokines in MCAO rats, including interleukin (IL)-1β, IL-4, IL-6, IL-8, IL-10 and tumor necrosis factor (TNF)-α. In addition, SUF also inhibited MMP2 and MMP9 and promoted the expression of collagen IV, indicating that SUF attenuated the destruction of the BBB. SUF also inhibited caspase3 and Bax rats and promoted Bcl2 in MCAO rats, thus inhibiting cell apoptosis. SUF pretreatment effectively improved the neurological function and cerebral infarction of MCAO rats, inhibited excessive inflammation in rats, protected the BBB, and inhibited cell apoptosis in brain tissue.

show abstract

“…Sufentanil is a lipophilic opioid agonist that is selective for µ-opioid receptors and can therefore exert analgesic and sedative effects ( 8 ). Compared with fentanyl and remifentanil, sufentanil not only reduces the incidence of postoperative nausea and vomiting, but also maintains stable hemodynamics ( 9 , 10 ).…”

Section: Introductionmentioning

confidence: 99%

Sufentanil ameliorates oxygen‑glucose deprivation/reoxygenation‑induced endothelial barrier dysfunction in HCMECs via the PI3K/Akt signaling pathway

Wang

Zhang

2022

Exp Ther Med

View full text Add to dashboard Cite

Ischemic heart disease, a chronic myocardial damage disease caused by coronary artery ischemia, is the leading cause of death worldwide. The aim of the present study was to explore the efficacy of sufentanil in myocardial ischemia/reperfusion (I/R) injury. Oxygen and glucose deprivation/reoxygenation (OGD/R) was utilized to induce human cardiac microvascular endothelial cells (HCMECs) to simulate myocardial I/R injury in vitro . The Cell Counting Kit-8 assay was used to detect the effects of sufentanil on HCMECs and OGD/R-induced HCMECs. The TUNEL, lactate dehydrogenase (LDH) activity, immunofluorescence and in vitro permeability assays, were used to assess apoptosis, LDH activity, VE-cadherin protein expression levels and endothelial barrier function in OGD/R-induced HCMECs, respectively. Moreover, western blotting was performed to assess the protein expression levels of apoptosis, endothelial barrier function and phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt)-related proteins. The results demonstrated that sufentanil had no significant influence on the viability of HCMECs but increased the viability of OGD/R-induced HCMECs in a dose-dependent manner. Furthermore, sufentanil inhibited cell apoptosis and permeability of OGD/R-induced HCMECs but enhanced the protein expression levels of tight junction proteins, including ZO-1, Occludin, VE-cadherin and Claudin-5. Sufentanil was also demonstrated to activate the PI3K/Akt signaling pathway. In addition, the use of LY294002, an inhibitor of the PI3K/Akt signaling pathway, partially abolished the protective effects of sufentanil on apoptosis, permeability and tight junction protein expression levels. These results indicated that sufentanil ameliorated OGD/R-induced endothelial barrier dysfunction in HCMECs, potentially via the PI3K/Akt signaling pathway. The present study therefore suggested that sufentanil may serve as a novel therapeutic option for the improvement of myocardial I/R injury.

show abstract

Sufentanil Sublingual Tablet: A New Option for Acute Pain Management

Cited by 13 publications

References 19 publications

Sedation, Analgesia, and Paralysis in COVID-19 Patients in the Setting of Drug Shortages

Sedation, Analgesia, and Paralysis in COVID-19 Patients in the Setting of Drug Shortages

Sufentanil alleviates cerebral ischemia-reperfusion injury by inhibiting inflammation and protecting the blood-brain barrier in rats

Sufentanil ameliorates oxygen‑glucose deprivation/reoxygenation‑induced endothelial barrier dysfunction in HCMECs via the PI3K/Akt signaling pathway

Contact Info

Product

Resources

About